Originally published by our sister publication Clinical Oncology News
By Clinical Oncology News Staff
The FDA has approved atezolizumab and hyaluronidase-tqjs (Tecentriq Hybreza, Genentech) for subcutaneous injection for all the adult indications as the intravenous formulation of atezolizumab (Tecentriq, Genentech), including non-small cell lung cancer (NSCLC), small cell lung cancer, hepatocellular carcinoma, melanoma and alveolar soft part sarcoma.
The subcutaneous injection of